Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ)
CNY 3.85
(-4.7%)
CNY 3.85
(-4.7%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.16 Billion CNY | 44.59% |
| 2022 | 804.82 Million CNY | -4.73% |
| 2021 | 844.79 Million CNY | 7.82% |
| 2020 | 783.54 Million CNY | -22.19% |
| 2019 | 1 Billion CNY | 15.86% |
| 2018 | 869.08 Million CNY | 5.2% |
| 2017 | 826.1 Million CNY | 21.42% |
| 2016 | 680.38 Million CNY | 7.6% |
| 2015 | 632.31 Million CNY | -12.91% |
| 2014 | 726.01 Million CNY | -1.11% |
| 2013 | 734.14 Million CNY | 11.58% |
| 2012 | 657.93 Million CNY | 5.98% |
| 2011 | 620.81 Million CNY | 80.12% |
| 2010 | 344.67 Million CNY | 284.13% |
| 2009 | 89.72 Million CNY | -9.13% |
| 2008 | 98.74 Million CNY | -8.97% |
| 2007 | 108.47 Million CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 1.31 Billion CNY | 4.59% |
| 2024 Q1 | 1.21 Billion CNY | 4.74% |
| 2024 Q2 | 1.26 Billion CNY | 3.55% |
| 2023 Q2 | 954.19 Million CNY | 14.48% |
| 2023 Q3 | 1.17 Billion CNY | 23.38% |
| 2023 FY | 1.16 Billion CNY | 44.59% |
| 2023 Q4 | 1.16 Billion CNY | -1.15% |
| 2023 Q1 | 833.47 Million CNY | 3.56% |
| 2022 Q2 | 968.05 Million CNY | 9.03% |
| 2022 Q1 | 887.86 Million CNY | 5.1% |
| 2022 FY | 804.82 Million CNY | -4.73% |
| 2022 Q4 | 804.82 Million CNY | -20.27% |
| 2022 Q3 | 1 Billion CNY | 4.27% |
| 2021 Q3 | 981.37 Million CNY | 4.44% |
| 2021 Q2 | 939.63 Million CNY | 13.13% |
| 2021 Q1 | 830.6 Million CNY | 6.01% |
| 2021 Q4 | 844.79 Million CNY | -13.92% |
| 2021 FY | 844.79 Million CNY | 7.82% |
| 2020 Q2 | 1.04 Billion CNY | 6.4% |
| 2020 Q4 | 783.54 Million CNY | -20.85% |
| 2020 Q1 | 985.63 Million CNY | -2.12% |
| 2020 FY | 783.54 Million CNY | -22.19% |
| 2020 Q3 | 989.94 Million CNY | -5.61% |
| 2019 Q2 | 990.32 Million CNY | 13.03% |
| 2019 FY | 1 Billion CNY | 15.86% |
| 2019 Q4 | 1 Billion CNY | 3.3% |
| 2019 Q3 | 974.82 Million CNY | -1.57% |
| 2019 Q1 | 876.12 Million CNY | 0.81% |
| 2018 Q4 | 869.08 Million CNY | -12.98% |
| 2018 Q1 | 846.41 Million CNY | 2.46% |
| 2018 FY | 869.08 Million CNY | 5.2% |
| 2018 Q2 | 1.02 Billion CNY | 21.35% |
| 2018 Q3 | 998.67 Million CNY | -2.77% |
| 2017 Q1 | 679.84 Million CNY | -0.08% |
| 2017 FY | 826.1 Million CNY | 21.42% |
| 2017 Q4 | 826.1 Million CNY | 15.51% |
| 2017 Q3 | 715.2 Million CNY | 1.32% |
| 2017 Q2 | 705.87 Million CNY | 3.83% |
| 2016 FY | 680.38 Million CNY | 7.6% |
| 2016 Q4 | 680.38 Million CNY | 3.57% |
| 2016 Q3 | 656.94 Million CNY | 4.57% |
| 2016 Q1 | 661.99 Million CNY | 4.69% |
| 2016 Q2 | 628.2 Million CNY | -5.11% |
| 2015 Q3 | 739.05 Million CNY | -3.02% |
| 2015 Q1 | 767.17 Million CNY | 5.67% |
| 2015 Q4 | 632.31 Million CNY | -14.44% |
| 2015 FY | 632.31 Million CNY | -12.91% |
| 2015 Q2 | 762.1 Million CNY | -0.66% |
| 2014 FY | 726.01 Million CNY | -1.11% |
| 2014 Q3 | 769.42 Million CNY | -7.97% |
| 2014 Q1 | 783.73 Million CNY | 6.75% |
| 2014 Q4 | 726.01 Million CNY | -5.64% |
| 2014 Q2 | 836.04 Million CNY | 6.67% |
| 2013 Q4 | 734.14 Million CNY | -2.63% |
| 2013 Q3 | 753.94 Million CNY | 2.1% |
| 2013 Q2 | 738.45 Million CNY | 6.19% |
| 2013 FY | 734.14 Million CNY | 11.58% |
| 2013 Q1 | 695.42 Million CNY | 5.7% |
| 2012 Q2 | 652.15 Million CNY | 5.9% |
| 2012 FY | 657.93 Million CNY | 5.98% |
| 2012 Q4 | 657.93 Million CNY | -6.48% |
| 2012 Q3 | 703.52 Million CNY | 7.88% |
| 2012 Q1 | 615.81 Million CNY | -0.81% |
| 2011 Q4 | 620.81 Million CNY | 0.66% |
| 2011 Q3 | 616.74 Million CNY | 7.18% |
| 2011 Q2 | 575.43 Million CNY | 59.02% |
| 2011 Q1 | 361.85 Million CNY | 4.98% |
| 2011 FY | 620.81 Million CNY | 80.12% |
| 2010 Q3 | 263.6 Million CNY | 26.05% |
| 2010 Q1 | 157.9 Million CNY | 75.99% |
| 2010 Q2 | 209.12 Million CNY | 32.43% |
| 2010 FY | 344.67 Million CNY | 284.13% |
| 2010 Q4 | 344.67 Million CNY | 30.76% |
| 2009 FY | 89.72 Million CNY | -9.13% |
| 2009 Q4 | 89.72 Million CNY | 0.0% |
| 2008 FY | 98.74 Million CNY | -8.97% |
| 2007 FY | 108.47 Million CNY | 0.0% |